| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(in millions, except per share data) | Quarter Ended December 31, 2022 | | Full-Year Ended December 31, 2022 |
| Acquired IPR&D and Milestones Expense | | Adjusted Diluted EPS Range | | Acquired IPR&D and Milestones Expense | | Adjusted Diluted EPS Range |
| | Low | | High | | | Low | | High |
Previously announced guidance excluding Q4 2022 acquired IPR&D and milestones expense | $ | — | | | $ | 3.65 | | | $ | 3.69 | | | $ | 454 | | | $ | 13.84 | | | $ | 13.88 | |
Q4 2022 acquired IPR&D and milestones expense | 243 | | | (0.14) | | | (0.14) | | | 243 | | | (0.14) | | | (0.14) | |
Guidance including Q4 2022 acquired IPR&D and milestones expense | $ | 243 | | | $ | 3.51 | | | $ | 3.55 | | | $ | 697 | | | $ | 13.70 | | | $ | 13.74 | |